Repurposing bromocriptine for Aβ metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations.
Takayuki KondoHaruhiko BannoTaro OkunomiyaYoko AminoKayoko EndoAkiyoshi NakakuraRyuji UozumiAkemi KinoshitaHarue TadaSatoshi MoritaHidehiro IshikawaAkihiro ShindoKen YasudaYosuke TarunoTakakuni MakiTakashi SuehiroKohji MoriManabu IkedaKoji FujitaYuishin IzumiKazutomi KanemaruKenji IshiiKazue ShigenobuYumiko KutokuYoshihide SunadaShinobu KawakatsuShunji ShiotaToshifumi WatanabeOsamu UchikawaRyosuke TakahashiHidekazu TomimotoHaruhisa InouePublished in: BMJ open (2021)
jRCT2041200008, NCT04413344.